• Nenhum resultado encontrado

Rev. Bras. Hematol. Hemoter. vol.33 número6

N/A
N/A
Protected

Academic year: 2018

Share "Rev. Bras. Hematol. Hemoter. vol.33 número6"

Copied!
1
0
0

Texto

(1)

484 Rev Bras Hematol Hemoter. 2011;33(6):484

Bone marrow cytomorphological changes in patients co-infected with visceral

leishmaniasis and human immunodeficiency virus

Images in Clinical Hematology

1

Pathology Department, Universidade Federal do Ceará – UFC, Fortaleza, CE, Brazil

2

Department of Clinical Analysis and Toxicology, Universidade Federal do Ceará – UFC, Fortaleza, CE, Brazil

3

Department of Clinical Medicine, Universidade Federal do Ceará – UFC, Fortaleza, CE, Brazil

Alana Jocelina Montenegro de Castro1

Romelia Pinheiro Gonçalves2

Maria Helena da Silva Pitombeira3

Visceral leishmaniasis (VL) is a severe systemic infectious disease.(1) It has been recognized as

an opportunistic disease in patients infected with human immunodeficiency virus (HIV).(2,3) The

analysis of the bone marrow of patients co-infected with VL and HIV showed dysplasia of erythroid, granulocytic and megakaryocytic lineages (Figure 1), besides the presence of plasmacytosis, cytoplasmic bodies, hemophagocytosis, granuloma and intracellular and extracellular leishmania amastigotes (Figure 2). These findings are found in the analysis of bone marrow of patients co-infected with HIV and VL; knowledge of these findings may be useful for the diagnosis and prognosis of patients.

Keywords: HIV infections; Bone marrow examination; Leishmaniasis, visceral; AIDS-related opportunistic infections

Conflict-of-interest disclosure: The authors declare no competing financial interest

Submitted: 10/18/2011 Accepted: 10/21/2011

Corresponding author:

Romelia Pinheiro Gonçalves Departamento de Análises Clínicas e Toxicológicas, Universidade Federal do Ceará – UFC

Rua Capitão Francisco Pedro 1210 Rodolfo Teófilo

60430-370 – Fortaleza, CE, Brazil romelia.pinheiro@pq.cnpq.br

www.rbhh.org or www.scielo.br/rbhh

DOI: 10.5581/1516-8484.20110129

Figure 1 – Dysplastic changes in erythroid, granulocytic and megakaryocytic lineages in marrow aspirate of patients co-infected with visceral leishmaniasis and human immunodeficiency virus on Leishman stain (magnification: 1000x) (A) dyserythropoiesis; (B) dysgranulopoiesis; (C) dysmegakaryopoiesis

Figure 2 – Bone marrow cytomorphological changes in patients co-infected with visceral leishmaniasis and human immunodeficiency virus on Leishman stain (magnification: 1000x) (A) multiple lobulated megakaryocyte; (B) Plasmacytosis; (C) Cytoplasmic body – extracellular leishmania amastigotes; (D) Hemophagocytosis and dysmegakaryopoiesis; (E) Granuloma; (F) leishmania amastigotes phagocytosed by macrophages

References

1. Jawhar NM. Visceral Leishmaniasis with an Unusual Presentation in an HIV positive patient. Sultan Qaboos Univ Med J. 2011;11(2):269-72.

Imagem

Figure 2 – Bone marrow cytomorphological changes in patients co-infected with visceral leishmaniasis and human immunodeficiency virus on Leishman stain (magnification: 1000x)  (A) multiple lobulated megakaryocyte; (B) Plasmacytosis; (C) Cytoplasmic body –

Referências

Documentos relacionados

The myelodysplastic syndromes (MDS), acute myeloid leukemias (AML) and secondary myeloproliferative syndromes (MPS) constitute a group of myeloid neoplasias (MNs) which result

High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the

Methods: Eighty-six adult patients with iron deficiency anemia, who had intolerance or showed no effect with oral iron therapy, received a weekly dose of 200 mg of intravenous

The O blood group phenotype of the ABO histo-blood group system is associated with allergic rhinitis in male but not in female

for all people is emphasized and to gradually evaluate the various models of access to high-cost treatments and the possibility of cooperation between Latin American centers

transcripts or suboptimal molecular responses (fluctuations at high BCR-ABL levels, i.e. 10%-1% on the IS at 18 months) are associated with increased risk of resistance due

On the other hand, it is very well known that oral iron is a less than ideal treatment mainly because of gastrointestinal AEs (particularly when using ferrous iron compounds), lack

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid